Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
Athira Pharma Inc
AVEO Pharmaceuticals Inc
Beijing SH biotechnology Co Ltd
G&P Bioscience Co Ltd
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
PlateletBio
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
Ad-HGF - Drug Profile
Product Description
Mechanism Of Action
ATH-1020 - Drug Profile
Product Description
Mechanism Of Action
History of Events
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
History of Events
doperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
History of Events
ficlatuzumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
fosgonimeton - Drug Profile
Product Description
Mechanism Of Action
History of Events
GB-102 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate HGF for Liver Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to activate HGF for Lung Injury - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
Product Description
Mechanism Of Action
Monoclol Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NK-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
oremepermin alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
SL-186 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SL-188 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Jul 25, 2022: Athira Pharma to present clinical and preclinical data at Alzheimer’s Association Intertiol Conference 2022
Jun 22, 2022: Athira Pharma announces topline results from ACT-AD Phase 2 proof of concept study of Fosgonimeton in mild-to-moderate Alzheimer’s disease
May 09, 2022: Athira Pharma extends ongoing open label extension study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for mild to moderate Alzheimer’s Disease
May 02, 2022: Helixmith announces VM202 (Engensis) presentation at New York Academy of Sciences "Advances in Pain" Meeting on May 3, 2022
Apr 05, 2022: Athira doses first subject in Phase I neuropsychiatric treatment trial
Mar 30, 2022: Athira Pharma highlights strong execution of strategy and positioning for the future
Mar 20, 2022: Athira Pharma presents study overview and baseline data from ACT-AD phase 2 trial of Fosgonimeton in mild-to-moderate Alzheimer’s Disease at the 2022 AD/PD Congress
Mar 14, 2022: Athira Pharma to present overview and update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer’s disease at AD/PD 2022 Congress
Mar 14, 2022: Paper reporting results from Helixmith’s phase 3 gene therapy trial for painful diabetic neuropathy was one of the top-10 most-downloaded articles in Clinical and Translatiol Science
Feb 22, 2022: Athira Pharma to present preclinical data at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting
Feb 22, 2022: Athira Pharma to present preclinical data of fosgonimeton at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting
Feb 22, 2022: Athira Pharma announces publication of phase 1 results for Fosgonimeton (ATH-1017) in The Jourl of Alzheimer’s Disease
Jan 25, 2022: Athira Pharma announces initiation of patient dosing in SHAPE, a phase 2 clinical trial of ATH-1017 for the treatment of Parkinson’s Disease dementia and dementia with lewy bodies
Dec 09, 2021: Kringle Pharma announces last patient out in phase 2 study of KP-100IT for the treatment of ALS
Nov 10, 2021: Athira Pharma presents overview and update from ACT-AD and LIFT-AD trials of ATH-1017 in mild-to-moderate Alzheimer’s disease at CTAD Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AnGes Inc, 2022
Pipeline by Athira Pharma Inc, 2022
Pipeline by AVEO Pharmaceuticals Inc, 2022
Pipeline by Beijing SH biotechnology Co Ltd, 2022
Pipeline by G&P Bioscience Co Ltd, 2022
Pipeline by Helixmith Co Ltd, 2022
Pipeline by i2 Pharmaceuticals Inc, 2022
Pipeline by Kringle Pharma Inc, 2022
Pipeline by Minerva Biotechnologies Corp, 2022
Pipeline by Molecular Partners AG, 2022
Pipeline by PlateletBio, 2022
Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
Pipeline by Yooyoung Pharm Co Ltd, 2022
Dormant Products, 2022
Discontinued Products, 2022